Health information — Educational information, not medical advice. Talk with your healthcare provider about your care and treatment decisions.
In 2026, we have more ways to prevent HIV than at any point in history — a daily pill, a twice-yearly injection, emergency medication, STI prevention, testing, condoms, and harm reduction. This hub covers all of them, in plain language, for everyone.
38,793
new HIV diagnoses in the U.S. and seven territories in 2024[1]
If a possible HIV exposure happened within 72 hours, seek a PEP assessment now. Start as soon as possible, ideally within 24 hours, when indicated. The prescribed course lasts 28 days; do not wait for symptoms or a routine appointment. [15]
You deserve prevention without judgment. Worry after an exposure, uncertainty about a partner, or difficulty paying for care can make the next step feel hard. You do not need a perfect explanation to ask for help. Start with the time-sensitive advice above, then use this hub at your own pace.
Start with the tools that match what you need today. The sections below introduce related options together, then connect you to their full guides. PrEP, U=U, testing, STI prevention, and harm reduction serve different needs; practical support helps make those options reachable.
Answer four questions for suggested reading and practical topics to bring to a prevention visit. Start with your situation, then explore the guides at your own pace.
Question 1 of 40%
Reading suggestions only — not an eligibility assessment. A healthcare provider can evaluate your specific situation and recommend the most appropriate prevention strategy for you.
PrEP is HIV prevention medication for people without HIV. A daily pill or a longer-acting injection may fit your life differently, and each option has its own eligibility, testing, and follow-up requirements. Use these guides to compare the routines and prepare questions for a provider.
Daily Oral PrEP
Daily oral PrEP reduces HIV risk from sex by about 99% when taken as prescribed. There are two oral regimens: F/TDF (emtricitabine/tenofovir disoproxil fumarate; Truvada or generic) and F/TAF (Descovy). F/TAF is not approved for receptive vaginal exposure. Coverage and assistance vary; ask about medication, appointment, and lab costs.[12]
Injectable PrEP can suit people who prefer fewer dosing days. Apretude requires two initiation visits one month apart, then injections every two months. Yeztugo requires oral doses when starting plus injections, then injections every 26 weeks. Both need timely appointments and HIV testing; trial results are not a guarantee for every individual.[12][16]
Prevention is a choice of tools, not a test of how many you use. Choose what fits your exposures, preferences, and access to care. U=U already means zero risk of sexual transmission; other tools can address different needs.
These examples are starting points for a conversation with your clinician about the tools that fit your body, relationships, and life. Care should respect your choices.
PrEP plus HIV testing on the schedule for your regimen; STI screening based on your exposures and risk, often every 3–6 months; doxy-PEP if appropriate; and condoms when desired.[12]
With sustained viral suppression on ART, the partner living with HIV does not transmit HIV through sex. The HIV-negative partner can still choose PrEP, including for other partners or personal reassurance. Discuss STI screening together.
Injectable PrEP avoids a daily pill schedule, but still requires timely injections and HIV testing. Apretude starts with injections one month apart, then every two months. Yeztugo requires oral initiation doses and injections, followed by injections every 26 weeks. Arrange a plan for any missed visit.[12][16]
Sterile injection equipment, naloxone, HIV/hepatitis testing, and access to care are key. Daily oral F/TDF PrEP is recommended for HIV risk through injection drug use. Injectable PrEP is approved for sexual exposure; protection against sharing injection equipment has not been established.[12]
Seek PEP assessment immediately after a possible exposure, ideally within 24 hours and no later than 72 hours. If prescribed, complete 28 days. Follow-up HIV tests are generally at baseline, 4–6 weeks, and 12 weeks after exposure; discuss a direct transition to PrEP if risk continues.[15]
Missed doses and access gaps happen. Tell your provider promptly so they can assess your protection, possible need for PEP, and a plan to restart or bridge medication. Adding another prevention method can help, but does not guarantee protection after a lapse.[12][15]
When someone living with HIV is on treatment and maintains an undetectable viral load, they cannot sexually transmit HIV to their partners. This isn't a hopeful theory. It is established science reflected in CDC and NIH guidance. Making HIV care accessible supports people’s health and sustained viral suppression. Several major studies support U=U. In PARTNER2, 782 gay male couples contributed eligible follow-up including 76,088 condomless anal sex acts while the partner with HIV had a viral load below 200 copies/mL. There were zero linked transmissions.[13]
U=U applies to sexual transmission when viral load is undetectable and stays that way — typically defined as under 200 copies/mL confirmed over time. After an interruption, do not assume suppression continues: contact the care team about restarting, viral-load testing, and prevention during any uncertainty. It also does not protect against other STIs. It should not be extended to sharing injection equipment, pregnancy, or breastfeeding; those routes have separate prevention recommendations. NIH guidance explains the distinction.
U=U can make room for satisfying sex lives, dating, and long-term relationships. The emotional and practical questions still deserve space: disclosure, trust, sharing care, and talking with a partner who is learning the science. These guides bring those pieces together.
Planning a pregnancy? Mixed-status couples where the partner living with HIV is on treatment and undetectable can conceive through condomless sex without sexual HIV transmission. The HIV-negative partner may choose PrEP, but it is not required to make U=U work. Talk with an HIV-experienced provider about timing, prenatal care, and HIV testing and preventive antiretroviral medicines for an infant exposed to HIV. If the pregnant partner has HIV, treatment and appropriate infant care reduce transmission during pregnancy and birth to below 1%; U=U does not mean zero perinatal risk. NIH and DHHS Perinatal Guidelines are the primary references.[8]
CDC recommends at least one HIV test for everyone aged 13–64 and at least annual testing for people with ongoing risk. Some sexually active gay and bisexual men may benefit from testing every 3–6 months. PrEP has its own testing schedule. A negative test during its window period does not rule out a recent infection.[18]
HIV prevention is one part of sexual health. Condoms and other barriers, DoxyPEP for eligible people, and hepatitis prevention address different questions. The introductions below explain how each fits, followed by guides and places to find support.
Condoms & Barrier Methods
External and internal condoms reduce HIV and many other STI risks when used correctly and consistently. They provide less protection against infections spread through uncovered skin. Doxy-PEP and vaccines can also prevent certain STIs; choose methods that fit your needs. Ask local sexual-health programs about free supplies.[17]
Doxy-PEP prevents some bacterial STIs, not HIV. CDC recommends discussing it with gay and bisexual men and transgender women who had syphilis, chlamydia, or gonorrhea in the past 12 months. The prescribed dose is 200 mg as soon as possible within 72 hours after oral, vaginal, or anal sex, no more than 200 mg in 24 hours. In studied populations, syphilis and chlamydia fell by over 70% and gonorrhea by about 50%. Discuss side effects, resistance, and follow-up testing with your clinician.[11]
Hepatitis A, B, and C are different viruses, so prevention starts with understanding which tests and vaccines apply to you. These guides connect prevention questions, test results, and follow-up, with a printable checklist for your next visit.
Syringe services programs provide sterile equipment and disposal, testing, naloxone, and links to treatment without requiring abstinence. CDC reports that SSPs are associated with an estimated 50% reduction in HIV and hepatitis C incidence. Effects and cost savings vary across settings.[10]
A prevention plan needs to be workable as well as effective. Cost, insurance, travel, privacy, and the way you are treated at a clinic can all shape whether care is within reach. Start with help paying for services, then explore support for the barriers getting in your way.
Coverage & Who Pays
Insurance, manufacturer assistance, and local PrEP services can help with prevention costs. Eligibility and covered services vary. ADAP supports treatment for people with HIV; it does not pay for PrEP. Use these resources to ask about medication, appointment, and lab costs before you start.
Under ACA preventive-services rules, most nongrandfathered private plans cover recommended PrEP and related services with no cost-sharing when applicable requirements are met. Coverage rules and timing can differ by plan and medication; ask about in-network services and any prior authorization.[7]
Need help paying for PrEP?[14] Current options include manufacturer medication assistance for eligible patients and state or local PrEP services. A PrEP navigator can help check which costs are covered; medication assistance may not cover appointments or lab work.
Access can be limited by distance to a provider, insurance statements sent to a parent, other privacy concerns, immigration status, incarceration, and provider stigma. Naming the specific barrier is usually the first step to routing around it.
Young people ages 13–24 account for a substantial share of new HIV diagnoses, and access to prevention often runs into consent laws, insurance-on-a-parent's-plan privacy fears, and clinics that don't feel safe to visit.[9] Prevention still works — the plumbing around it just needs to be built for youth.
Truvada is FDA-approved for adolescents weighing at least 35 kg. Descovy is approved for sexual exposure except receptive vaginal sex; eligibility follows the exposure route, not sex assigned at birth. Yeztugo (lenacapavir) is approved for adults and adolescents weighing at least 35 kg.[5]
The South accounts for roughly half of all new HIV diagnoses in the U.S. every year, at a rate of about 17.7 per 100,000 — well above every other region.[1] Florida sits near the top of that list. The tools work here; the geography, coverage patchwork, and criminalization laws make them harder to reach. This section maps the region-specific pieces.
Florida law allows counties to authorize syringe exchange programs under specific conditions, including one-for-one exchange; availability varies by county. SSPs are associated with about 50% lower HIV incidence among people who inject drugs.[10] This walks through what to expect on a first visit and how to find one.
Where HIV prevention in America stands as of September 2026 — the science that's advancing, the coverage that shifted, and the fights ahead. New tools have arrived faster than most people realize, but access remains uneven.
The FDA approved Yeztugo (lenacapavir) on June 18, 2025 — the first PrEP option with dosing every six months. Compared with estimated background HIV incidence, PURPOSE 1 found 100% efficacy among cisgender women and PURPOSE 2 found 96% efficacy in a predominantly male study population.[5]
Gilead's once-weekly oral lenacapavir (Yeztugo tablet) has an FDA target action date of February 2, 2027. If approved, it would be the first long-acting pill for HIV prevention.[6]
CDC reported 38,793 diagnoses in the U.S. and seven territories in 2024. Its U.S. care indicators report 69% viral suppression among people diagnosed by end-2023 and alive at end-2024, and 83% linkage within one month among new diagnoses. About 22% of U.S. diagnoses were already stage 3 (AIDS).[1]
The Supreme Court decided Kennedy v. Braidwood 6–3 on June 27, 2025, upholding ACA preventive-services coverage — including no-cost PrEP — for people enrolled in plans subject to those requirements.[7]
Real questions from the community — on PrEP, PEP, harm reduction, and everything in between.
No — oral and injectable PrEP protect against HIV only. They do not prevent syphilis, gonorrhea, chlamydia, herpes, HPV, or other STIs. Condoms provide protection against most STIs. DoxyPEP can reduce bacterial STIs (syphilis, chlamydia, and to a lesser extent gonorrhea) for eligible individuals. This is why comprehensive sexual health care — including regular STI testing — remains important even when you’re on PrEP.
For daily oral F/TDF, maximum drug levels associated with protection are reached after about 7 days for receptive anal sex and up to about 21 days for receptive vaginal sex and injection drug use. The time to maximum protection for insertive sex is not established. Injectable regimens have their own initiation schedules. Ask your clinician when your prescribed regimen provides protection.[12]
Daily oral F/TDF PrEP is recommended for people at risk through injection drug use. CDC estimates at least 74% lower HIV risk when oral PrEP is taken as prescribed. Injectable PrEP is approved for sexual exposure; protection from sharing injection equipment has not been established. Sterile equipment and access to harm-reduction services remain essential.[12]
Continue your prescribed PrEP and contact your clinician promptly after a possible exposure if you have missed doses, delayed an injection, or have symptoms suggesting acute HIV. PEP may be needed after a lapse and must be assessed within 72 hours. Do not wait until the next routine appointment to discuss a possible protection gap. HIV-testing schedules differ by PrEP regimen.[12][15]
Doxy-PEP can cause stomach upset, irritation of the esophagus, and sun sensitivity. Long-term effects on antibiotic resistance and the microbiome remain uncertain. CDC recommends shared decision-making for gay and bisexual men and transgender women with a bacterial STI in the past 12 months, with reassessment every 3–6 months; evidence is insufficient for a blanket recommendation for everyone. [11]
Florida permits county-authorized syringe exchange programs under the Infectious Disease Elimination Act. Programs must follow statutory conditions, including one-for-one exchange. Availability varies by county; contact a local program to confirm services and participation requirements. See the syringe-services guide and statutory source.
Switching may be possible after HIV testing, medication and hepatitis B review, and a plan for the transition. Ask when to take the final oral doses, when protection from the new regimen begins, and what happens if an injection is late. Do not stop or bridge medication on your own. [12][16]Compare the options and follow-up schedules.
Many insurance plans cover PrEP, but the product, network, authorization rules, and visit or laboratory charges matter. Manufacturer assistance and public or community programs may help eligible people. [14] Ask a PrEP navigator to check the specific program; free medication does not necessarily mean free visits or labs. Florida ADAP is for people diagnosed with HIV and is not a PrEP benefit. Explore assistance options.
PrEP can be used during pregnancy and breastfeeding when clinically appropriate. Daily F/TDF has substantial pregnancy safety data and is recommended for receptive vaginal exposure. F/TAF (Descovy) is not approved for that route. Injectable options require a discussion of available safety evidence, dosing, and HIV testing with a clinician; pregnancy does not remove the need for HIV prevention.[12][16]
PrEP (Pre-Exposure Prophylaxis) is taken before a potential exposure — either as a daily pill or periodic injection — to prevent HIV acquisition in people who are HIV-negative and at ongoing risk. PEP (Post-Exposure Prophylaxis) is an emergency 28-day course of medication started within 72 hours after a possible HIV exposure. PrEP is ongoing prevention; PEP is emergency treatment. If you've needed PEP more than once, you're likely a strong candidate for PrEP. Compare all prevention options.
A note on this content: The information on this hub covers HIV prevention methods including PrEP, PEP, DoxyPEP, condoms, and testing. It is provided for educational purposes only and is not medical advice. The right prevention strategy depends on your individual health history, risk factors, and circumstances. Always consult a qualified healthcare provider before starting, stopping, or changing any prevention medication. For questions about HIV exposure, criminal disclosure obligations, or your legal rights, consult a provider and, where appropriate, a legal professional familiar with HIV law. Full disclaimer →
Clinical and policy guidance below draws on CDC, NIH, FDA, court opinions, and other identified sources. The hub summarizes the evidence; the linked guides provide further detail. Eligibility, coverage, and local services can change.
Gilead Sciences. Yeztugo (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection.gilead.com↩
Gilead Sciences. FDA Accepts Application for Investigational Once-Weekly Oral Yeztugo.gilead.com↩
U.S. Supreme Court. Kennedy v. Braidwood Management, Inc., No. 24–316, June 27, 2025. The Court upheld the appointment structure of the USPSTF; this preserved the challenged preventive-services coverage framework. Opinion (PDF). ↩
CDC. HIV Testing and Youth (Ages 13–24). Youth testing data, barriers, and access considerations; local consent and privacy rules require confirmation. cdc.gov — HIV Testing and Youth↩
CDC. Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.MMWR Recommendations and Reports. 2024;73(2):1–8. DOI: 10.15585/mmwr.rr7302a1. cdc.gov/mmwr/volumes/73/rr/rr7302a1.htm↩
Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. The Lancet. 2019;393(10189):2428–2438. (PARTNER2) thelancet.com↩
CDC — Clinical Recommendation for the Use of Lenacapavir for HIV Preexposure Prophylaxis, United States, 2025. Source. Checked September 20, 2026. ↩
CDC — Condom Use: An Overview. Source. Checked September 20, 2026. ↩
CDC — HIV Testing: routine, annual, and more frequent testing recommendations. Source. Checked September 20, 2026. ↩
Trusted community publications — POZ, Positively Aware, TheBody, and aidsmap — provide lived-experience context and plain-language reporting we consult when framing this material. Factual claims on this page are anchored to the primary sources above.
